Short Sellers Circle Outlook Therapeutics at Record Pace as FDA Verdict Looms
29.06.2026 - 04:11:59 | boerse-global.de
The clock is ticking down to July 29, and the tension surrounding Outlook Therapeutics is palpable. While the biotech’s stock has staged a remarkable recovery from its 52-week low of $0.16 in March 2026, short sellers are piling in at an alarming rate. Short interest surged by 77.5% to 16.1 million shares, now representing 16.7% of all outstanding stock — a more than sevenfold increase over the past twelve months. The bearish conviction is rising in lockstep with the regulatory stakes.
But the company has just cleared one administrative hurdle. After facing a potential delisting from the Nasdaq in February — when the stock dipped below the $1 minimum bid price — Outlook Therapeutics finally regained compliance. The share price stayed above the threshold for ten consecutive trading days from June 11 to June 25, earning the exchange’s green light. On Friday, the stock closed at $1.71, up 6.21% on the day, and has rallied roughly 192% over the last 30 days. Year-to-date, the gain stands at 159%. Yet the relative strength index sits at 74 — technically overbought — and the annualized volatility exceeds 230%, underlining the wild swings that accompany this binary bet.
All eyes are now fixed on the PDUFA deadline of July 29, 2026, when the FDA will rule on the company’s resubmitted Biologics License Application for ONS-5010/LYTENAVA™, a bevacizumab candidate for neovascular age-related macular degeneration. The agency classified the submission as a Class-1 review, signaling a shorter evaluation period, and has already indicated that data from the NORSE-TWO study, along with confirmatory results from NORSE EIGHT, provide substantial evidence of efficacy. The FDA has even instructed its relevant division to finalize product labeling with the company — a bullish sign that has not gone unnoticed by bulls. Approval would make LYTENAVA™ the first FDA-approved ophthalmic bevacizumab product.
Should investors sell immediately? Or is it worth buying Outlook Therapeutics?
Across the Atlantic, the drug is already commercialized. LYTENAVA™ holds centralized marketing authorization in the EU and approval from the UK’s MHRA, with commercial sales underway in Germany, Austria, and Britain. While second-quarter fiscal 2026 European sales dipped roughly 10% sequentially, management reports an uptick in the current quarter. A distribution agreement with Mediconsult AG targets a Swiss launch in 2027. In the U.S., preparations for a rollout are proceeding, though the company’s financial position casts a long shadow.
Outlook Therapeutics ended March 2026 with just $7.7 million in cash and equivalents, burning through approximately $7.8 million per quarter. Management itself has expressed substantial doubt about the company’s ability to continue as a going concern. Dilutive financing — direct placements, convertible notes with warrants — has been the pattern, and another capital raise appears almost certain. For the fiscal first quarter of 2026, Outlook reported a net loss of $0.16 per share, missing the analyst consensus of $0.12. As a development-stage firm, it generated no revenue.
Analysts are split. BTIG downgraded the stock to Neutral in May, citing an unclear U.S. approval pathway and weak European sales. Ascendiant Capital, by contrast, maintains a $10.00 price target. The stock has already rallied more than tenfold from its 52-week trough, but remains 42% below its 52-week high of $2.97. The market is pricing in a real but uncertain probability of approval. For bulls, the streamlined Class-1 review and the chance to create a first-in-class product justify the risk. For bears, the cash burn, dilution threat, and memory of previous complete response letters from the FDA are enough to keep betting against it. On July 29, only one side will be right.
Ad
Outlook Therapeutics Stock: New Analysis - 29 June
Fresh Outlook Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
